PAVmed (PAVM) Net Margin (2021 - 2026)

PAVmed has reported Net Margin for 6 years, with the latest figure at 16603.03% in Q2 2026.

• On a quarterly basis, Net Margin rose 20519697.0% year-over-year to 16603.03% in Q2 2026; TTM through Jun 2026 was 21578.4%, a 2072616.0% decrease from a year earlier, with the FY2025 full-year figure at 3800.0%, down 486731.0% from the prior year.
• Net Margin was 16603.03% for Q2 2026 at PAVmed, down from 2293.83% in the prior quarter.
• The five-year high for Net Margin was 221250.0% in Q1 2025, with the low at 221800.0% in Q2 2025.
• Average Net Margin over 5 years is 16537.43%, with a median of 8802.41% recorded in 2023.
• The largest YoY upside for Net Margin was 22350624 bps in 2025 against a maximum downside of 22068580 bps in 2025.
• Over 5 years, Net Margin stood at 18332.14% in 2022, then jumped by 92 bps to 1516.21% in 2023, then slumped by 1240 bps to 20320.0% in 2024, then soared by 89 bps to 2293.83% in 2025, then slumped by 624 bps to 16603.03% in 2026.
• The last three Net Margin figures came in at 16603.03% (Q2 2026), 2293.83% (Q4 2025), and 126560.0% (Q3 2025), per Business Quant data.